Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling

Objective: Bevacizumab is a recombinant humanized monoclonal antibody that blocks vascular endothelial growth factor (VEGF) with clear clinical benefits. However, overall survival of some cancer types remains low owing to resistance to bevacizumab therapy. While resistance is commonly ascribed to tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaoling, Zhang, Yan, Jia, Yanan, Qin, Tingting, Zhang, Cuicui, Li, Yueya, Huang, Chengmou, Liu, Zhujun, Wang, Jing, Li, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309466/
https://www.ncbi.nlm.nih.gov/pubmed/32587778
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309466/
https://www.ncbi.nlm.nih.gov/pubmed/32587778
http://dx.doi.org/10.20892/j.issn.2095-3941.2019.0215

Ejemplares similares